Search

Your search keyword '"Maillard L"' showing total 641 results
Start Over Author "Maillard L"
641 results on '"Maillard L"'

63. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI

Author

Hulot, Jean-Sébastien, primary, Chevalier, Bernard, additional, Belle, Loic, additional, Cayla, Guillaume, additional, Khalife, Khalife, additional, Funck, François, additional, Berthier, Romain, additional, Piot, Christophe, additional, Tafflet, Muriel, additional, Montalescot, Gilles, additional, Hulot, Jean-Sébastien, additional, Belle, Loïc, additional, Le Breton, Hervé, additional, Teiger, Emmanuel, additional, Dambrin, Grégoire, additional, Khalife, K., additional, Schmutz, L., additional, Funck, F., additional, Berthier, R., additional, Piot, C., additional, Hannebicque, G., additional, Montalescot, G., additional, Lognone, T., additional, De Poli, F., additional, Chevalier, B., additional, Lhoest, N., additional, Schneeberger, M., additional, Delarche, N., additional, Faure, A., additional, Aelion, H., additional, Godin, M., additional, Gilard, M., additional, Ritz, B., additional, Barraud, P., additional, Barnay, P., additional, Saïdi, L.N., additional, Le Dref, O., additional, Garot, P., additional, Range, G., additional, Georges, J., additional, Robin, C., additional, Cottin, Y., additional, Belle, L., additional, Souteyrand, G., additional, Lafont, A., additional, Fournier, A., additional, Dupouy, P., additional, Shayne, J., additional, Chapon, P., additional, Boureux, C., additional, Faure, J.P., additional, Ben Amer, H., additional, Furber, A., additional, Ormezzano, O., additional, Bayet, G., additional, Karrillon, G., additional, Maillard, L., additional, Grenzinger, A., additional, Avran, A., additional, Koning, R., additional, Dumant, D., additional, Lamit, X., additional, Dauphin, R., additional, Drogoul, L., additional, Cuisset, T., additional, Wittenberg, O., additional, Peyre, J.P., additional, Laury, P., additional, and Robert, R., additional

Published
2020
Full Text
View/download PDF

65. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial

Author

Tomaniak, M, Chichareon, P, Onuma, Y, Deliargyris, EN, Takahashi, K, Kogame, N, Modolo, R, Chang, CC, Rademaker-Havinga, T, Storey, RF, Dangas, GD, Bhatt, DL, Angiolillo, DJ, Hamm, C, Valgimigli, M, Windecker, S, Steg, PG, Vranckx, P, Serruys, PW, Bertrand, OF, Plante, S, Van Geuns, RJ, Hofma, SH, Royaards, KJ, Slagboom, T, Suryapranata, H, Umans, VAWM, Rensing, B, van der Harst, P, Magro, M, Barbato, E, Aminian, A, Benit, E, Janssens, L, Vrolix, M, Buysschaert, I, Carrie, D, Barraud, P, Teiger, E, Koning, R, Farzin, B, Morelle, JF, Isaaz, K, Maillard, L, Abdellaoui, M, Brunel, P, Angioi, M, Lantelme, P, Sabate, M, Gonzalez-Trevilla, AA, Cequier, A, Iiguez, A, Penaranda, AS, Miguel, CM, Diaz, JF, Antolin, RAH, Goicolea, J, Ribeiro, VG, da Silva, PC, Ferreira, RC, Almeida, M, Ungi, I, Merkely, B, Fontos, G, Horvath, I, Koszegi, Z, Jambrik, Z, Edes, I, Jozsef, F, Colombo, A, Bolognese, L, Ferrario, M, Tumscitz, C, Dominici, M, Curello, S, Roffi, M, Eeckhout, E, Moccetti, T, Moschovitis, A, Leibundgut, G, Huber, K, Frey, B, Delle Karth, G, Friedrich, G, Steinwender, C, Zweiker, R, Stables, R, Anderson, R, Chowdhary, S, Garg, S, Hildick-Smith, D, Fath-Ordoubadi, F, Oldroyd, KG, Galasko, G, Kukreja, N, Zaman, A, Subkovas, E, Curzen, N, Hoole, S, Talwar, S, Walsh, S, Adlam, D, Cotton, J, Holmvang, L, Ottesen, MM, Buszman, P, Zurakowski, A, Galuszka, G, Prokopczuk, J, Zmudka, K, Jasionowicz, P, Mlodziankowski, A, Liebetrau, C, Naber, CK, Neumann, FJ, Schchinger, V, Seidler, T, Ibrahim, K, Zrenner, B, Gori, T, Werner, N, Akin, I, Geisler, T, vom Dahl, J, Haude, M, Eitel, I, Krackhardt, F, Jung, W, Neto, PAL, Sousa, A, Quintella, EF, Leandro, S, Botelho, R, Raffel, C, Barlis, P, Hai, KT, Ong, P, Petrov, I, Konteva, M, Velchev, V, Gelev, V, Tonev, G, Valkov, V, Vassilev, D, and Trendafilova-Lazarova, D

Abstract

Key PointsQuestionWhat are the benefits and risks of continuing aspirin in addition to P2Y12 receptor inhibition with ticagrelor among patients with acute coronary syndrome between 1 month and 12 months after percutaneous coronary intervention? FindingsIn this nonprespecified, post hoc analysis of the GLOBAL LEADERS randomized clinical trial, beyond 1 month after percutaneous coronary intervention in acute coronary syndrome, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events. MeaningThe findings of this hypothesis-generating analysis pave the way for further trials evaluating aspirin-free antiplatelet strategies after percutaneous coronary intervention. ImportanceThe role of aspirin as part of antiplatelet regimens in acute coronary syndromes (ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. ObjectiveTo evaluate the benefit and risks of aspirin in addition to ticagrelor among patients with ACS beyond 1 month after percutaneous coronary intervention (PCI). Design, Setting, and ParticipantsThis is a nonprespecified, post hoc analysis of GLOBAL LEADERS, a randomized, open-label superiority trial comparing 2 antiplatelet treatment strategies after PCI. The trial included 130 secondary/tertiary care hospitals in different countries, with 15991 unselected patients with stable coronary artery disease or ACS undergoing PCI. Patients had outpatient visits at 1, 3, 6, 12, 18, and 24 months after index procedure. InterventionsThe experimental group received aspirin plus ticagrelor for 1 month followed by 23-month ticagrelor monotherapy; the reference group received aspirin plus either clopidogrel (stable coronary artery disease) or ticagrelor (ACS) for 12 months, followed by 12-month aspirin monotherapy. In this analysis, we examined the clinical outcomes occurring between 31 days and 365 days after randomization, specifically in patients with ACS who, within this time frame, were assigned to receive either ticagrelor alone or ticagrelor and aspirin. Main Outcomes and MeasuresThe primary outcome was the composite of all-cause death or new Q-wave myocardial infarction. ResultsOf 15968 participants, there were 7487 patients with ACS enrolled; 3750 patients were assigned to the experimental group and 3737 patients to the reference group. Between 31 and 365 days after randomization, the primary outcome occurred in 55 patients (1.5%) in the experimental group and in 75 patients (2.0%) in the reference group (hazard ratio [HR], 0.73; 95% CI, 0.51-1.03; P=.07); investigator-reported Bleeding Academic Research Consortium-defined bleeding type 3 or 5 occurred in 28 patients (0.8%) in the experimental group and in 54 patients (1.5%) in the reference arm (HR, 0.52; 95% CI, 0.33-0.81; P=.004). Conclusions and RelevanceBetween 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events. These findings should be interpreted as exploratory and hypothesis generating; however, they pave the way for further trials evaluating aspirin-free antiplatelet strategies after PCI. Trial RegistrationClinicalTrials.gov identifier: NCT01813435. This secondary analysis of the GLOBAL LEADERS randomized clinical trial evaluates the benefit and risks of aspirin in addition to ticagrelor among patients with acute coronary syndrome beyond 1 month after percutaneous coronary intervention.

Published
2019

67. 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent

Author

Xu, B., Saito, Y., Baumbach, A., Kelbaek, H., Royen, N. van, Zheng, M., Morel, M.A., Knaapen, P., Slagboom, T., Johnson, T.W., Vlachojannis, G., Arkenbout, K.E., Holmvang, L., Janssens, L., Ochala, A., Brugaletta, S., Naber, C.K., Anderson, R., Rittger, H., Berti, S., Barbato, E., Toth, G.G., Maillard, L., Valina, C., Buszman, P., Thiele, H., Schachinger, V., Lansky, A., Wijns, W., Xu, B., Saito, Y., Baumbach, A., Kelbaek, H., Royen, N. van, Zheng, M., Morel, M.A., Knaapen, P., Slagboom, T., Johnson, T.W., Vlachojannis, G., Arkenbout, K.E., Holmvang, L., Janssens, L., Ochala, A., Brugaletta, S., Naber, C.K., Anderson, R., Rittger, H., Berti, S., Barbato, E., Toth, G.G., Maillard, L., Valina, C., Buszman, P., Thiele, H., Schachinger, V., Lansky, A., and Wijns, W.

Abstract

Item does not contain fulltext, OBJECTIVES: The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove-filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE (Abbott Vascular, Santa Clara, California), a durable-polymer everolimus-eluting coronary stent. BACKGROUND: The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial. METHODS: The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. RESULTS: At 2-year follow-up, the incidence of target lesion failure was 8.7% in the Firehawk group versus 8.6% in the XIENCE group (p = 0.92). The event rates of individual components of the primary endpoint were comparable for the 2 groups. Landmark analyses between 1- and 2-year follow-up revealed no statistically significant difference of TLF for the Firehawk versus the XIENCE stent. Beyond 1 year, very late definite or probable stent thrombosis occurred in 3 patients (0.4%) in the Firehawk group and in 7 patients (0.9%) in the XIENCE group (p = 0.34). CONCLUSIONS: The 2-year follow-up of the TARGET All Comers study confirms comparable safety and efficacy profiles of the Firehawk and XIENCE stents.

Published
2019

76. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial

Author

Lansky, A., Wijns, W., Xu, B., Kelbaek, H., Royen, N. van, Zheng, M., Morel, M.A., Knaapen, P., Slagboom, T., Johnson, T.W., Vlachojannis, G., Arkenbout, K.E., Holmvang, L., Janssens, L., Ochala, A., Brugaletta, S., Naber, C.K., Anderson, R., Rittger, H., Berti, S., Barbato, E., Toth, G.G., Maillard, L., Valina, C., Buszman, P., Thiele, H., Schachinger, V., Baumbach, A., Lansky, A., Wijns, W., Xu, B., Kelbaek, H., Royen, N. van, Zheng, M., Morel, M.A., Knaapen, P., Slagboom, T., Johnson, T.W., Vlachojannis, G., Arkenbout, K.E., Holmvang, L., Janssens, L., Ochala, A., Brugaletta, S., Naber, C.K., Anderson, R., Rittger, H., Berti, S., Barbato, E., Toth, G.G., Maillard, L., Valina, C., Buszman, P., Thiele, H., Schachinger, V., and Baumbach, A.

Abstract

Item does not contain fulltext, BACKGROUND: The FIREHAWK is a drug-eluting stent with a fully biodegradable sirolimus-containing polymer coating localised to recessed abluminal grooves on the stent surface. We investigated clinical outcomes with this targeted, low-dose, biodegradable polymer, sirolimus-eluting stent compared with XIENCE durable polymer, everolimus-eluting stents in an all-comers population. METHODS: The TARGET All Comers study was a prospective, multicentre, open-label randomised non-inferiority trial done at 21 centres in ten European countries. Patients with symptomatic or asymptomatic coronary artery disease and objective evidence of myocardial ischaemia who qualified for percutaneous coronary intervention were randomised 1:1 to undergo implantation of a FIREHAWK or XIENCE. Randomisation was web-based, with random block allocation and stratification by centre and ST elevation myocardial infarction. Outcome assessors were masked to treatment allocation, but treating physicians and patients were not. The primary endpoint was target lesion failure at 12 months, a composite of cardiac death, target vessel myocardial infarction, or ischaemia-driven target lesion revascularisation. The control event rate for XIENCE was assumed to be 7%, the non-inferiority margin was 3.5%, and the primary analysis was in the intention-to-treat population, censoring patients who did not have either an event before 365 days or contact beyond 365 days. Late lumen loss was the primary endpoint of an angiographic substudy designed to investigate the non-inferiority of the FIREHAWK compared with the XIENCE stent. This trial is registered with ClinicalTrials.gov, number NCT02520180. FINDINGS: From Dec 17, 2015, to Oct 14, 2016, 1653 patients were randomly assigned to implantation of the FIREHAWK (n=823) or XIENCE (n=830). 65 patients in the FIREHAWK group and 66 in the XIENCE group had insufficient follow-up data and were excluded from the analyses. At 12 months, target lesion failure occurred in 46 (6.1%)

Published
2018

77. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System

Author

Cutlip, DE, Garratt, KN, Novack, V, Barakat, M, Meraj, P, Maillard, L, Erglis, A, Jauhar, R, Popma, JJ, Stoler, R, Silber, S, Serra, A., and Monassier, Jean Pierre

Subjects
restenosis, stent(s), thrombosis
Abstract

OBJECTIVES The aim of this study was to assess the safety and effectiveness of the COBRA Polyzene-F NanoCoated Coronary Stent System (CeloNova Biosciences, San Antonio, Texas) for the treatment of de novo coronary artery lesions. BACKGROUND Polyzene-F-coated coronary stents have shown reduced thrombogenicity and inflammation in preclinical studies. METHODS Patients with de novo coronary artery lesions meeting eligibility criteria were enrolled in a nonrandomized, prospective clinical trial. The primary endpoint was target vessel failure (TVF) (defined as a composite of cardiac death, myocardial infarction, or clinically driven target vessel revascularization) at 9 months. A pre-specified subset was planned for routine repeat angiographic follow-up at 9 months. The powered secondary endpoint was mean late lumen loss (LL). The comparator was a performance goal derived from meta-analysis of historical bare-metal stent trials of 19.62% for TVF and 1.1 mm for LL. Other secondary endpoints were clinically driven target lesion revascularization and definite or probable stent thrombosis. RESULTS Of 296 enrolled patients, 287 (97%) completed primary endpoint analysis; 130 were planned for angiographic follow-up and 115 (88%) completed. At 9 months, TVF had occurred in 33 patients (11.5%; upper 95% confidence boundary: 15.07%), including 1 (0.3%) cardiac death, 20 (7.0%) myocardial infarctions (17 periprocedural), and 17 (5.9%) target vessel revascularizations. LL was 0.84 +/- 0.48 mm (upper 95% confidence boundary: 0.92). Target lesion revascularization occurred in 13 patients (4.6%). There were no stent thrombosis events. CONCLUSIONS The COBRA Polyzene-F stent met performance goals for TVF and LL at 9 months. There was an excellent safety profile, with infrequent late myocardial infarction and no stent thrombosis. (C) 2017 by the American College of Cardiology Foundation.

Published
2017

79. Thyroid liposarcoma: a case report

Author

Gerard Maxime, Flaris Alexander N., Demarchi Marco, El Boukili Ilies, Maillard Laure, Borson-Chazot Françoise, Decaussin-Petrucci Myriam, and Lifante Jean-christophe

Subjects
sarcoma, thyroid liposarcoma, thyroid surgery, Surgery, RD1-811
Abstract

Thyroid liposarcoma is a rare tumor. Its low prevalence accounts for the scarcity of data in the literature, which consists mostly of small studies and case reports.

Published
2022
Full Text
View/download PDF

80. Preliminary results on effectiveness of marker-assisted seedling selection applied to Mendelian traits in peach

Author

Mauroux, J.B., primary, Diévart, V., additional, Tuéro, C., additional, Maillard, L., additional, Maillard, A., additional, Aranzana, M.J., additional, Eduardo, I., additional, Batlle, I., additional, Cantin, C., additional, Marcaillou, J.C., additional, Mendoza, O.C., additional, Bassi, D., additional, Pacheco, I., additional, Foschi, S., additional, and Pascal, T., additional

Published
2017
Full Text
View/download PDF

82. The Face-Processing Network Is Resilient to Focal Resection of Human Visual Cortex

Author

UCL - SSH/IPSY - Psychological Sciences Research Institute, Weiner, K. S., Jonas, Jacques, Gomez, J., Maillard, L., Brissart, H., Hossu, G., Jacques, Corentin, Loftus, D., Colnat-Coulbois, S., Stigliani, A., Barnett, M. A., Grill-Spector, K., Rossion, Bruno, UCL - SSH/IPSY - Psychological Sciences Research Institute, Weiner, K. S., Jonas, Jacques, Gomez, J., Maillard, L., Brissart, H., Hossu, G., Jacques, Corentin, Loftus, D., Colnat-Coulbois, S., Stigliani, A., Barnett, M. A., Grill-Spector, K., and Rossion, Bruno

Published
2016

85. Harnuntersuchung

Author

Riegler, E., Albahary, Kutscher, Fr., Steudel, H., Schöndorff, Beyer, C., Fingerling, G., Morgen, A., Malfatti, H., Bredig, G., Brown, J. W., Bayer, Al., Siegfried, M., Krüger, M., Reich, O., Donzé, G., Lambling, E., Sellerin, Ch., Dimmock, A. F., Branson, F. W., Hall, Walker, Porcher, Ch., Hervieux, Ch., Gnezda, Jul., Maillard, L., Ellinger, Al., Bouma, J., Schlesinger, W., and Garrod, Arch. E.

Published
1904
Full Text
View/download PDF

86. Randomised comparison of coronary stenting with and without balloon predilatation in selected patients

Author

Breton, H Le, Boschat, J, Commeau, P, Brunel, P, Guard, M, Breut, C, Bar, O, Geslin, P, Tirouvanziam, A, Maillard, L, Moquet, B, Barragan, P, Dupouy, P, Grollier, G, Berland, J, Druelles, P, Rihani, R, Huret, B, Leclercq, C, and Bedossa, M

Subjects
Coronary heart disease -- Care and treatment, Stent (Surgery) -- Methods, Health, Care and treatment, Methods
Abstract

Abstract Background--The SWIBAP (stent without balloon predilatation) prospective randomised trial was designed to compare direct coronary stenting with stenting preceded by lesion predilatation with an angioplasty balloon. Objective--To determine the [...]

Published
2001

92. Syndecan-4 intracellular domain orchestrates rantes/CCL5-induced monocyte arrest on endothelial cell monolayer under flow

Author

Maillard, L., primary, Friand, V., additional, Suffee, N., additional, Hlawaty, H., additional, Haddad, O., additional, Chmilewsky, F., additional, Backhouche, S., additional, Desbois, E., additional, Oudar, O., additional, Letourneur, D., additional, Saito, N., additional, Ueyama, T., additional, Charnaux, N., additional, and Sutton, A., additional

Published
2014
Full Text
View/download PDF

98. Évaluation de l’exactitude de latéralisation du foyer épileptogène par la tomographie par émission de positons au 18f-fluorodésoxyglucose dans le bilan préopératoire de l’épilepsie temporale : analyse visuelle simple et par index d’asymétrie inter-hémisphérique par soustraction d’images, analyse quantitative par statistical parametric mapping

Author

Yagdigul, Y., primary, Verger, A., additional, Van Der Gucht, A., additional, Poussier, S., additional, Maillard, L., additional, Roch, V., additional, Karcher, G., additional, and Marie, P.-Y., additional

Published
2014
Full Text
View/download PDF

100. The factors of the geographical concentration of the agricultural productions an analysis for the European Union

Author

Daniel, Karine, Maillard, L., ProdInra, Migration, Economie et Droit Rural et Agro-Alimentaire, and Institut National de la Recherche Agronomique (INRA)

Subjects
LOCALISATION, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, POLITIQUE AGRICOLE COMMUNE, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, Environnement, espace et société
Abstract

A également fait l'objet d'une présentation au Séminaire INRA-ESR : Economie de la production les 28-29/11/2000 à Paris; Cet article présente une analyse de la concentration géographique des productions agricoles au niveau communautaire. Les auteurs y examinent, à partir de régressions économétriques, dans quelle mesure les coûts de production agricoles et l'accès aux marchés conditionnent l'évolution relative de la localisation des productions. Ils montrent ainsi que la localisation des productions, soutenues dans le cadre de la politique agricole commune, est indépendante de ces déterminants. Pour tous les produits non soutenus, la position géographique des bassins de production par rapport à la localisation de la demande communautaire conditionne l'évolution de la production. Ainsi, au niveau de l'Union européenne, pour les productions non soutenues, on se situe dans un schéma de concentration géographique conditionnée par la localisation de la demande, plutôt que dans un scénario de spécialisation des espaces productifs selon le jeu d'avantages comparatifs purement agricoles.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results